Clinical trials: Bronchial Neoplasms
Solid Tumors, Urothelial Carcinoma
A Study Evaluating MM-310 in Patients With Solid Tumors
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid…
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03076372
- Testing
- MM-310
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Merrimack Pharmaceuticals
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Carcinoma, Non-Small-Cell Lung
Afatinib Osimertinib Sequencing NIS
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line…
- Trial name
- NCT03370770
- Testing
- Afatinib, Osimertinib
- Where
- Austria
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Carcinoma
ZD6474 Phase IIa Dose Finding Multicentre Study
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
- Trial name
- NCT00252746
- Testing
- ZD6474 (vandetanib) 100mg, ZD6474 (vandetanib) 200mg, ZD6474 (vandetanib) 300mg
- Where
- 7 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Genzyme, a Sanofi Company
Non-Small Cell Lung Cancer
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line…
- Trial name
- NCT05654454
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 28 sites in Russia
- Volunteers
- 620 people
- Sponsor
- Mabscale, LLC
Non-small Cell Lung Cancer, Pancreatic Cancer
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under…
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT04803305
- Testing
- PF-06946860
- Where
- 33 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Pfizer
Lung Cancer
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records. Increased lung cancer screening programs and increased utilization of other screening modalities such as…
- Trial name
- DIASTAG (NCT06842056)
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ).
- Trial name
- METRIX (NCT06068842)
- Where
- 19 sites in Argentina, Brazil and 10 more
- Volunteers
- 579 people
- Sponsor
- AbbVie
Non-small Cell Lung Cancer
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01792479
- Testing
- BIND-014
- Where
- 17 sites in United States, Russia
- Volunteers
- 64 people
- Sponsor
- BIND Therapeutics
Colorectal Cancer, Breast Cancer
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in…
- Conditions
- Colorectal Cancer, Breast Cancer, Pancreas Cancer, Ovarian Cancer
- Trial name
- NCT04640480
- Testing
- SNB-101
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- SN BioScience
Non-small Cell Lung Cancer
To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.
It's a Phase Ib/II clinical trial to evaluate the efficacy and safety of TQB3728 tablets in sequential maintenance TQB2450 injection therapy in patients after sequential or concurrent chemoradiation for locally advanced non-small…
- Trial name
- NCT05859373
- Testing
- TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation, TQB2450 injection, sequential or concurrent chemoradiation
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Small Cell Lung Cancer
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
This was a Phase II, open-label, prospective, multicenter study designed to evaluate the efficacy and safety of single-agent atezolizumab as a first-line therapy in participants with locally advanced or metastatic non-small cell…
- Trial name
- B-F1RST (NCT02848651)
- Testing
- Atezolizumab
- Where
- 20 sites in United States
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
CLDN6-positive Solid Tumor, Ovarian Cancer
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Before a treatment can be approved for use, clinical studies need to be done. This study is for people with certain types of cancer that have become worse and are difficult to treat.
- Conditions
- CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT06681870
- Testing
- ASP1893
- Sponsor
- Astellas Pharma Global Development, Inc.
Non-Small Cell Lung Cancer
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00965731
- Testing
- Erlotinib, PF-02341066
- Where
- 16 sites in United States
- Volunteers
- 27 people
- Sponsor
- Pfizer
NSCLC, Non Small Cell Lung Cancer
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with unresectable or metastatic non-small cell lung cancer…
- Trial name
- NCT07806773
- Testing
- TUB-040
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Gilead Sciences
Non-Small Cell Lung Cancer
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT05005273
- Testing
- Nivolumab, Ipilimumab, BMS-986207
- Where
- 71 sites in United States, Argentina and 10 more
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties.
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
- Trial name
- NCT05860296
- Testing
- SLC-391, pembrolizumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- SignalChem Lifesciences Corporation
Carcinoma，Non-Small-Cell Lung
Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment
The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in [14C] AC0010 ADME.
- Trial name
- NCT03053219
- Testing
- AC0010
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Non-Small Cell Lung Cancer
KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)
The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth…
- Trial name
- KOREA (NCT02777567)
- Where
- South Korea
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Lung Cancer, Non Small Cell Lung Cancer (NSCLC)
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the effect of food on the pharmacokinetics (PK) of the experimental drug, entinostat, in women with breast cancer and men and women with non-small cell lung cancer.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
- Trial name
- ENCORE110 (NCT01594398)
- Testing
- entinostat, Erlotinib, Exemestane
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Syndax Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.